SPOTLIGHT: Brain cancer vaccine doubles survival time


An experimental brain cancer vaccine more than doubled the survival time of patients suffering from glioblastoma multiforme. Early-stage data demonstrated that patients lived almost three years after taking the vaccine for a disease that typically kills people after one year. Report

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.